siRNA for suppressing expression of programmed cell death ligand 1 gene, conjugates thereof, pharmaceutical compositions and uses thereof

SiRNAs with specific sequences and liver-targeting conjugates effectively suppress PD-L1 gene expression, addressing the limitations of existing PD-L1 drugs by enhancing stability and efficacy with reduced side effects.

JP2026506685APending Publication Date: 2026-02-25SUZHOU SIRAN BIOTECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2025547496
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2023-11-23
Publication Date
2026-02-25

AI Technical Summary

Technical Problem

Current drugs targeting PD-L1, such as antibodies and small molecules, have high systemic side effects and limited efficacy in treating hepatitis B, while nucleic acid drugs like ASOs are less effective and lack liver-specific delivery, and no PD-L1-targeting siRNA drugs are on the market or in clinical research.

Method used

Development of siRNAs with specific sequences and conjugates that target PD-L1 gene expression, featuring modified nucleotides and liver-specific delivery, enhancing stability and efficacy with reduced systemic side effects.

Benefits of technology

The siRNAs demonstrate high PD-L1 mRNA suppression activity with liver-targeting specificity, improving safety and long-term efficacy, allowing longer dosing intervals and better patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026506685000001_ABST
    Figure 2026506685000001_ABST
Patent Text Reader

Abstract

The present invention relates to siRNAs for suppressing the expression of programmed cell death ligand 1 gene, conjugates thereof, and pharmaceutical compositions, as well as uses thereof, wherein the siRNA comprises a sense strand and an antisense strand, and each nucleotide in the siRNA is independently modified or unmodified, the sense strand comprises any one of the nucleotide sequences set forth in SEQ ID NOs: 1 to 12, or a nucleotide sequence having not more than three base mutations in the above sequence, and the antisense strand comprises any one of the nucleotide sequences set forth in SEQ ID NOs: 13 to 24, or a nucleotide sequence having not more than five base mutations in the above sequence.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to siRNA for suppressing the expression of programmed cell death ligand 1 gene, its conjugate and pharmaceutical composition, and uses thereof. [Background technology]

[0002] Programmed cell death 1 ligand 1 (PD-L1) binds to cluster of differentiation 274 (CD274). 274 ) or B7 homolog 1 (B7-H1), CD 274 PD-L1 is a 40-kDa type I transmembrane protein encoded by a gene. PD-L1 is expressed on various tissue cells, including T cells, epithelial cells, and endothelial cells, and its expression is upregulated in many tumors.

[0003] PD-L1 is the primary ligand for PD-1. Interaction between the ligand PD-L1 and the receptor PD1 induces phosphorylation of intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), thereby suppressing T cell activation and cytokine production. During infection and inflammation in normal tissues, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In the tumor microenvironment, this interaction inactivates effector T cells, thereby providing immune escape for tumor cells.

[0004] Furthermore, a report by Sun Y et al. (Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G162-G173.) reported that viruses improve infectivity by modulating the PD-1 / PD-L1 pathway. During hepatitis B virus (HBV) infection, HBV increases PD-L1 expression via the PTEN / β-catenin / c-Myc signaling pathway, thereby suppressing T cell responses and ultimately promoting immune escape by HBV. Targeting this signaling pathway is a potential strategy for the treatment of chronic hepatitis B.

[0005] Currently, most of the drugs targeting PD-L1 that are on the market or in clinical trials are antibodies or small molecules, such as envolimab, suglimab, durvalumab, APL-502, and CA-170. The indications under investigation for these drugs are mainly in the oncology field, and they are administered systemically, resulting in a high incidence of side effects in clinical trials and low safety. There are few applications in the hepatitis B treatment field, and among the drugs currently on the market, only envolimab (ASC 22 ) is currently undergoing clinical trials in the United States for the indication of hepatitis B. In preclinical studies, ASCs were shown to be effective in a woodchuck model infected with hepatitis B virus. 22 The combination of ASC with entecavir has been shown to reduce surface antigen levels (Balsitis S et al., PLoS One. 2018 Feb 14;13(2):e0190058.). In Phase IIa clinical data, ASC at 0.3, 1.0, or 2.5 mg / kg was shown to be effective in reducing surface antigen levels (Balsitis S et al., PLoS One. 2018 Feb 14;13(2):e0190058.). 22 showed a dose-dependent reduction in HBsAg after a single dose.

[0006] Currently, in the field of nucleic acids, only one drug in the clinical stage for the treatment of hepatitis B is an oligonucleotide (ASO) drug RO-9191863 from Roche that targets PD-L1. Generally, ASOs are somewhat inferior to siRNA drugs in terms of efficacy and long-term efficacy, and because they have the property of systemic distribution, liver-specific delivery is not as good as that of siRNA drug forms conjugated with liver-targeting molecules. siRNA drugs target PD-L1 by conjugating with liver-targeting molecules. Targeted siRNA drugs can be delivered specifically to the liver, specifically downregulating the levels of PD-L1 molecules in the liver and reducing the systemic side effects of small molecule, antibody and ASO drug forms.

[0007] Although there are several patents for PD-L1-targeting siRNA, no PD-L1-targeting siRNA drugs have been launched on the market, and no PD-L1-targeting siRNA drugs are currently in clinical research. Therefore, there is a need for continuous development of siRNA drugs that can suppress PD-L1 gene expression. Summary of the Invention

[0008] The objective of the present invention is to provide the following siRNAs and modified sequences thereof, which can specifically suppress the expression of the PD-L1 gene in cells. Pharmaceutical compositions and siRNA conjugates comprising the siRNAs of the present disclosure can effectively deliver the siRNAs of the present disclosure to target tissues and / or cells, and thereby show great potential as pharmaceuticals for the treatment or prevention of diseases associated with PD-L1 expression.

[0009] To achieve the above objectives, the technical solutions adopted by the present invention are as follows:

[0010] A first aspect of the present invention provides an siRNA for suppressing expression of the programmed cell death ligand 1 gene, comprising a sense strand and an antisense strand, wherein the sense strand comprises any one of the nucleotide sequences set forth in SEQ ID NOs: 1 to 12, or a nucleotide sequence having not more than three base mutations in the above sequence, and the antisense strand comprises any one of the nucleotide sequences set forth in SEQ ID NOs: 13 to 24, or a nucleotide sequence having not more than five base mutations in the above sequence.

[0011] According to some embodiments, the sense strand comprises a nucleotide sequence having two or fewer base mutations, or a nucleotide sequence having one or fewer base mutations, relative to any one of the nucleotide sequences set forth in SEQ ID NOs: 1 to 12.

[0012] In some embodiments, the base mutation in the sense strand may be at any position in the nucleotide sequence, for example, at any one, two, or three of the following positions: first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, and nineteenth.

[0013] According to some embodiments, the antisense strand comprises a nucleotide sequence having five or fewer base mutations, four or fewer base mutations, three or fewer base mutations, two or fewer base mutations, or one or fewer base mutations relative to any one of the nucleotide sequences set forth in SEQ ID NOs: 13 to 24.

[0014] In some embodiments, the base mutation in the antisense strand may be at any position in the nucleotide sequence, for example, at any one, two, three, four or five of the following positions: first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, and twenty-first.

[0015] In some embodiments, in the 5' to 3' direction, the base mutations in the sense strand are at the 3' end of the nucleotide sequence, and the base mutations in the antisense strand are at any one or more of the 5' end, positions 2 to 8, or the last two positions of the 3' end of the nucleotide sequence.

[0016] According to some embodiments, the base mutation comprises a base substitution, insertion or deletion.

[0017] In some embodiments, the modified nucleotides are one or more combinations of 2'-methoxy modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-CH2-CH2-O-CH3 modified nucleotides, 2'-O-CH2-CH=CH2 modified nucleotides, 2'-CH2-CH2-CH=CH2 modified nucleotides, 2'-deoxynucleotides, 2'-methoxyethyl modified nucleotides, phosphorothioate bond modified nucleotides, VP modified nucleotides, LNA, ENA, cET BNA, UNA, GNA, and SAFE-01, wherein R1 in the structural formula of SAFE-01 is H, OH, or CH3, and Base is a natural nucleobase, modified nucleobase, universal base, or H atom.

[0018] Furthermore, R1 is CH3.

[0019] In some embodiments, the number of modified nucleotides in the sense strand is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19.

[0020] In some embodiments, the number of modified nucleotides in the antisense strand is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21.

[0021] In some embodiments, all nucleotides in the sense strand and the antisense strand are modified nucleotides.

[0022] In some embodiments, in the 5' to 3' direction, the nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro modified nucleotides, and the nucleotides at positions 2, 14, and 16 of the antisense strand are 2'-fluoro modified nucleotides.

[0023] In some further embodiments, the nucleotides at other positions in the sense strand are 2'-methoxy modified nucleotides.

[0024] In some further embodiments, in the 5' to 3' direction, position 6 of the antisense strand is a 2'-fluoro modified nucleotide or SAFE-01, and position 7 of the antisense strand is a 2'-methoxy modified nucleotide or SAFE-01.

[0025] Preferably, SAFE-01 is Ago, Ggo, Cgo or Ugo.

[0026] In some further embodiments, the nucleotides at other positions in the antisense strand are 2'-methoxy modified nucleotides, where the other positions refer to positions other than 2, 6, 7, 14, and 16.

[0027] In some further embodiments, at least one of the following internucleotide linkages in the siRNA is a phosphorothioate linkage: a bond between a first nucleotide and a second nucleotide at the 5' end of the sense strand; a linkage between the second and third nucleotides at the 5' end of the sense strand; a bond between a first nucleotide and a second nucleotide at the 3' end of the sense strand; a bond between the second and third nucleotides at the 3' end of the sense strand; a bond between a first nucleotide and a second nucleotide at the 5' end of the antisense strand; a linkage between the second and third nucleotides at the 5' end of the antisense strand; a bond between a first nucleotide and a second nucleotide at the 3' end of the antisense strand; The linkage between the second and third nucleotides at the 3' end of the antisense strand.

[0028] In some further embodiments, the 3' end of the sense strand is a phosphorothioate group and the 5' end of the antisense strand is a VP-modified nucleotide.

[0029] In some embodiments, the siRNA is selected from the sequences in Table 2 or Tables 3-1 and 3-2, and one sense strand and one antisense strand of one duplex number constitute one siRNA.

[0030] A second aspect of the present invention provides an siRNA conjugate, which comprises one or more of the siRNAs described above and a conjugate group conjugated to said siRNA.

[0031] In some embodiments, the conjugate group is derived from compound SA51, the structural formula of which is as follows: [ka] Furthermore, the number of compounds SA51 in the conjugate group is 2 to 4, and the 2 to 4 compounds SA51 are sequentially linked via chemical bonds.

[0032] In some embodiments, the conjugate group is linked to the 3'-end and / or the 5'-end of the sense strand.

[0033] In some embodiments, the structural formula of the siRNA conjugate is as follows: [ka]

[0034] A third aspect of the present invention provides a pharmaceutical composition, which comprises the above-mentioned siRNA or the above-mentioned siRNA conjugate, and a pharmaceutically acceptable carrier or excipient.

[0035] In some embodiments, the pharmaceutical composition is used to inhibit expression of the programmed cell death ligand 1 gene.

[0036] A fourth aspect of the present invention provides use of the above-mentioned siRNA, or the above-mentioned siRNA conjugate, or the above-mentioned pharmaceutical composition for the manufacture of a medicament for treating and / or preventing a disease associated with PD-L1 gene expression.

[0037] In some embodiments, the disease is viral hepatitis or cancer.

[0038] Furthermore, the viral hepatitis is caused by infection with hepatitis B virus, hepatitis C virus, or hepatitis D virus.

[0039] In some embodiments, the siRNA, or the siRNA conjugate, or the pharmaceutical composition is formulated to be administered to a subject according to a required dose.

[0040] In some embodiments, the siRNA, the siRNA conjugate, or the pharmaceutical composition is administered in the form of subcutaneous injection, intravenous injection, intrathecal injection, or intramuscular injection.

[0041] By applying the above technical solutions, the present invention has the following advantages compared with existing technologies:

[0042] The siRNA disclosed in the present invention is a human-derived PD-L1 siRNA sequence, and its conjugates and pharmaceutical compositions have good stability and high PD-L1 mRNA suppression activity. This siRNA drug has liver-targeting specificity and, compared to small molecule drugs and antibody drugs, has better safety and long-term efficacy, allowing for longer dosing intervals in clinical practice and better patient compliance. [Brief explanation of the drawings]

[0043] [Figure 1]FIG. 1 shows the results of an IC50 test of the siRNA of Example 5 in SNU-387 cells. [Figure 2] FIG. 2 shows the activity results of the siRNA of Example 7 in HDI mice on days 7 and 28. Specific Embodiments

[0044] It should be noted that unless otherwise specified, technical or scientific terms used herein should have the ordinary meanings that are understood by those skilled in the art.

[0045] The experimental methods in the following examples are conventional methods unless otherwise specified. Raw materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.

[0046] definition In the above and below, 2'-methoxy modified nucleotide refers to a nucleotide formed by substituting a methoxy group for the 2'-hydroxyl group of the ribose group of a nucleotide. Similarly, 2'-fluoro modified nucleotide, 2'-O-CH2-CH2-O-CH3 modified nucleotide, 2'-O-CH2-CH=CH2 modified nucleotide, 2'-CH2-C The terms H2-CH=CH2 modified nucleotide, 2'-deoxynucleotide, and 2'-methoxyethyl modified nucleotide refer to nucleotides formed by replacing the hydroxyl group at the 2' position of the ribose group of a nucleotide with the corresponding group.

[0047] A phosphorothioate-linked modified nucleotide refers to a nucleotide in which one oxygen atom of the phosphodiester bond in the phosphate group of the nucleotide is replaced with a sulfur atom.

[0048] A VP-modified nucleotide refers to a nucleotide formed by replacing the phosphate group of a nucleotide with a vinyl phosphate group, and in some embodiments, the phosphate group at the 5' end of the antisense strand is replaced with VP.

[0049] The LNA is shown in equation (1), the ENA is shown in equation (2), the cET BNA is shown in equation (3), the UNA is shown in equation (4), the GNA is shown in equation (5), and the VP is shown in equation (6): [ka] In the above formulas (1) to (6), Base represents a natural nucleobase, a modified nucleobase, or a universal base, such as A, U, G, or C. In the above formulas (4) to (6), R is selected from H, OH, or an alkoxy group (O-alkyl). The structural formula of SAFE-01 is [ka] wherein R1 is H, OH, or CH3, and Base is a natural nucleobase, a modified nucleobase, a universal base, or an H atom. According to some embodiments, R1 is H. According to some embodiments, R1 is OH. According to some embodiments, R1 is CH3.

[0050] In the above and below, particularly when describing the method for producing siRNA, pharmaceutical composition or siRNA conjugate of the present disclosure, unless otherwise specified, the nucleoside monomer refers to the modified or unmodified nucleoside phosphoramidite monomer used in solid-phase phosphoramidite synthesis according to the type and order of nucleotides in the siRNA or siRNA conjugate to be produced.Solid-phase phosphoramidite synthesis is a method used in RNA synthesis known to those skilled in the art.All nucleoside monomers used in the present disclosure are commercially available.

[0051] In the context of this disclosure, unless otherwise specified, "conjugation" refers to the covalent linking together of two or more chemical moieties, each having a specific function. Therefore, "conjugate" refers to a compound in which these chemical moieties are covalently bonded. Furthermore, "siRNA conjugate" refers to a compound in which one or more chemical moieties having specific functions are covalently bonded to siRNA. Depending on the context, siRNA conjugate should be understood as a general term for multiple siRNA conjugates or an siRNA conjugate represented by a certain chemical formula. In the context of the present disclosure, "conjugate molecule" should be understood as a specific compound that can be conjugated to siRNA by reaction to ultimately form the siRNA conjugate of the present disclosure.

[0052] A variety of hydroxyl protecting groups can be used in the present disclosure. Generally, protecting groups render a chemical functional group inert to specific reaction conditions and can be added to and removed from that functional group in a molecule without substantially damaging the remainder of the molecule. Representative hydroxyl protecting groups are disclosed in Beaucage et al., Tetrahedron 1992, 48, 2223-2311, and Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed., John Wiley & Sons, New York, 1991, each of which is incorporated herein by reference in its entirety. In some embodiments, the protecting group is stable under basic conditions but can be deprotected under acidic conditions. In some embodiments, non-exclusive examples of hydroxyl protecting groups that can be used herein include dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthen-9-yl (Pixyl), and 9-(p-methoxyphenyl)xanthen-9-yl (Mox). In some embodiments, non-exclusive examples of hydroxyl protecting groups that can be used herein include Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-dimethoxytrityl), and TMTr (4,4',4''-trimethoxytrityl).

[0053] Pharmaceutically acceptable carriers described in the present disclosure include carriers commonly used in the field of siRNA administration, such as magnetic nanoparticles (e.g., Fe3O4 or Fe2O3-based nanoparticles), carbon nanotubes, mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM) dendrimer, poly(L-lysine) (PLL), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly(D&L-lactic / glycolic acid) copolymer (PLGA), poly(2-aminoethyl ethylene phosphate), and the like. The excipient may be one or more of various agents or compounds commonly used in the art. For example, the pharmaceutically acceptable excipient may include at least one of a pH buffer, a protective agent, and an osmotic pressure adjusting agent.

[0054] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes cases where the event or circumstance occurs and cases where it does not occur.

[0055] The term "subject," as used herein, refers to any animal, e.g., a mammal or marsupial. Subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cows, rabbits, sheep, rats, and poultry of all kinds.

[0056] As used herein, "treatment" refers to a method of obtaining beneficial or desired results, including, but not limited to, therapeutic benefit. "Therapeutic benefit" refers to the eradication or amelioration of the underlying disorder being treated. Additionally, therapeutic benefit is obtained by the improvement observed in a subject by eradicating or ameliorating one or more physiological symptoms associated with the underlying disorder, even though the subject may still be afflicted with the underlying disorder.

[0057] As used herein, "prevention" refers to a method of obtaining beneficial or desired results, including, but not limited to, a prophylactic benefit. To obtain a "prophylactic benefit," an siRNA, siRNA conjugate, or pharmaceutical composition can be administered to a subject at risk of developing a particular disease, or to a subject who reports one or more physiological symptoms of a disease, even if the disease has not yet been diagnosed.

[0058] The technical solutions provided by the present invention will be further described below in conjunction with specific examples. The following examples are only used to illustrate the present invention and do not limit the protection scope of the present invention.

[0059] Example 1 Synthesis of siRNA Where the actual source of a reagent is not indicated in the text, such reagents may be obtained from any molecular biology reagent supplier and shall meet quality / purity standards appropriate for molecular biology applications.

[0060] Using solid support-mediated phosphoramidite chemistry, Dr. Oligo 48PD-L1 siRNA sequences were synthesized at a 200 nmol (nmol) scale on a Biolytic synthesizer. The solid support was a Universal Solid Support (Shenzhen Comma Bio). Nucleoside monomer raw materials, such as 2'-F RNA and 2'-O-methyl RNA, were purchased from Shanghai Zhaowei or Suzhou Jima. The coupling time for all amidites (50 mM acetonitrile solution) was 6 min. The activating agent was 5-ethylthio-1H-tetrazole (ETT) (0.6 M acetonitrile solution). The sulfurization reagent was 0.22 M PADS dissolved in a 1:1 volumetric solution of acetonitrile and trimethylpyridine (Suzhou Kolema). The sulfurization reaction time was 3 min. The oxidizing agent was iodine pyridine / water solution (Kolema), and the oxidation reaction time was 2 min.

[0061] After the solid-phase synthesis was completed, the oligoribonucleotide was cleaved from the solid support and soaked in a 3:1 solution of 28% aqueous ammonia and ethanol at 50°C for 16 hours. After that, it was centrifuged at high speed, and the supernatant was transferred to another centrifuge tube and concentrated and evaporated to dryness. 18 The oligonucleotides were purified by reverse-phase chromatography using a mobile phase of 0.1 M TEAA and acetonitrile, and DMTr was removed using 3% trifluoroacetic acid solution. The target oligonucleotides were recovered, lyophilized, and confirmed to be the desired product by LC-MS. They were then quantified by UV (260 nm).

[0062] The resulting single-stranded oligonucleotides were annealed with two complementary sequences in an equimolar ratio, and the resulting double-stranded siRNA was dissolved in 1X PBS and adjusted to the required concentration for the experiment. These monomers were linked to each other via 5'-3'-phosphodiester bonds to form the oligonucleotides.

[0063] Example 2 Preparation of siRNA conjugates 1. Preparation of Galnac targeting group In this example, the synthetic route of compound SA51 (I-1-7) is as follows: [ka]

[0064] 1. Preparation of intermediate 2-1 [ka] Compound (R)-(+)-N-benzyl-3-hydroxypyrrolidine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (16.9 mmol, 3.0 g) and imidazole (3.0 equiv, 50.7 mmol, 3.45 g) were placed in a clean, dry reaction flask, 50 mL of acetonitrile was added, and tert-butyldimethylchlorosilane (1.3 equiv, 21.9 mmol, 3.31 g) was slowly added at room temperature. The mixture was then stirred for 12 hours at room temperature. After the reaction, 100 mL of ethyl acetate was added to the reaction mixture, which was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 - 5 / 1) to give compound 2-1 (4.9 g, 16.8 mmol, 99% yield) as a colorless oil. Molecular formula of compound 2-1: C 17 H 29 ONSi, molecular weight: 291.2, LC-MS actual value: 292.4 (M+H).

[0065] 2.2 Preparation of Intermediate 2-2 [ka] Compound 2-1 (16.8 mmol, 4.9 g) was placed in a clean, dry reaction flask. To the mixture, 100 mL of methanol was added, and palladium on carbon (wet base, 10% Pd / C) (10% wt, 490.0 mg) was added at room temperature under a hydrogen atmosphere, followed by stirring at room temperature for 12 hours. After the reaction, the palladium on carbon was removed by filtration, and the filtrate was concentrated to obtain the crude product, compound 2-2 (3.31 g, 16.5 mmol, 98% yield), as a white solid. This was used in the next reaction without further purification. The molecular formula of compound 2-2 is C 10 H 23 ONSi, molecular weight: 201.1, LC-MS actual value: 202.3 (M+H).

[0066] 2.3 Preparation of Intermediate 2-3 [ka] Compound N-benzyloxycarbonyl-L-serine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (15.0 mmol, 3.58 g) was placed in a clean, dry reaction flask, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 22.5 mmol, 8.53 g), compound 2-2 (1.1 equiv, 16.5 mmol, 3.31 g), and N,N-diisopropylethylamine (3.0 equiv, 45.0 mmol, 5.78 g) were added at room temperature, followed by stirring at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction mixture, which was then washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 - 1 / 3) to obtain compound 2-3 (4.5 g, 10.65 mmol, 63% two-step yield) as a white solid. The molecular formula of compound 2-3 is C. 21 H 34 O5N2Si, molecular weight: 422.2, LC-MS observed value: 423.3 (M+H). 1H NMR (400 MHz, CDCl3): δ 7.35-7.29 (m, 5H), 5.96 (dd, J = 14.3, 8.3 Hz, 1H), 5.10 (s, 2H), 4.61 - 4.40 (m, 2H), 3.85 - 3.68 (m, 2H), 3.65 - 3.49 (m, 2H), 3.41 (d, J = 12.7 Hz, 1H), 3.31 (s, 1H), 1.95 (qdd, J = 15.0, 11.8, 5.3 Hz, 2H), 1.77 (s, 1H), 0.86 (s, 9H), 0.06 (d, J = 3.1 Hz, 6H).

[0067] 2.4 Preparation of Intermediate 2-4 [ka] Compound 2-3 (10.65 mmol, 4.5 g) was placed in a clean, dry reaction flask, 100 mL of pyridine was added, and 4,4'-bis(methoxy)trityl chloride (1.2 equiv, 12.78 mmol, 4.32 g) was added at room temperature. The mixture was then stirred for 12 hours at room temperature. After the reaction, 150 mL of ethyl acetate was added to the reaction mixture, which was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated saline. The organic phase was dried, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 - 1 / 1) to give compound 2-3, a pale yellow oil. Compound 2-4 (7.56 g, 10.43 mmol, 98% yield) was obtained. The molecular formula of compound 2-4 is: C 42 H 52 O7N2Si, molecular weight: 724.3, LC-MS observed value: 747.4 (M+Na). 1 H NMR (400 MHz, CDCl3): δ7.35-7.31 (m, 1H), 7.28 (d, J = 4.7 Hz, 4H), 7.27 - 7.23 (m, 2H), 7.23 - 7.14 (m, 5H), 7.13 - 7.11 (m, 2H), 6.80-6.78 (m, 1H), 6.76 (dd, J = 7.7, 5.4 Hz, 4H), 5.72 (dd, J = 22.7, 8.3 Hz, 1H), 5.08 - 4.99 (m, 2H), 4.69 - 4.59 (m, 1H), 4.35 - 4.30 (m, 1H), 3.73 (dd, J = 4.5, 3.7 Hz, 6H), 3.65 - 3.44 (m, 2H), 3.36 - 3.20 (m, 3H), 1.86 - 1.81 (m, 1H), 1.70 (s, 1H), 0.80 (d, J = 13.1 Hz, 9H), -0.02 (dd, J = 14.9, 4.2 Hz, 6H).

[0068] 2.5 Preparation of Intermediate 2-5 [ka] Compound 2-4 (10.43 mmol, 7.56 g) was placed in a clean, dry reaction flask, 100 mL of methanol was added, and palladium-carbon (wet base, 10% Pd / C) (10% wt, 750.0 mg) was added at room temperature under a hydrogen atmosphere. Stirring was then continued at room temperature for 12 hours. After the reaction, the palladium-carbon was removed by filtration, and the filtrate was concentrated to obtain the crude product, compound 2-5 (6.0 g, 10.22 mmol, 98% yield), as a white solid. This crude product was used in the next reaction without further purification. The molecular formula of compound 2-5 is C. 34 H 46 O5N2Si, molecular weight: 590.3, LC-MS measured value: 591.6 (M+H).

[0069] 2.6 Preparation of Intermediate 2-6 [ka] Compound 5-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (commercially available, purchased from Nuoganlin Biopharmaceutical Technology (Suzhou) Co., Ltd.) (2.06 g, 4.62 mmol) was placed in a clean, dry reaction flask, and 100 mL of dichloromethane was added. Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 6.93 mmol, 2.63 g) was added at room temperature and stirred for 10 minutes. Compound 2-5 (1.1 equiv, 5.08 mmol, 3.0 g) and N,N-diisopropylethylamine (3.0 equiv, 13.86 mmol, 17.91 g) were then added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction mixture, which was then washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1 - 10 / 1) to obtain compound 2-6 (3.58 g, 3. The compound 2-6 was obtained in an amount of 51 mmol (76% yield). The molecular formula of the compound 2-6 was: C 53 H 73 O 15 N3Si, molecular weight: 1019.3, LC-MS measured value: 1018.3 (MH).

[0070] 2.7 Preparation of Intermediate 2-7 [ka] Compound 2-6 (3.51 mmol, 3.58 g) was placed in a clean, dry reaction flask, 50 mL of pyridine was added, and triethylamine hydrogen fluoride (5.0 equiv, 17.55 mmol, 2.97 g) was added at room temperature. Stirring was then continued at room temperature for 12 hours. After the reaction, 100 mL of ethyl acetate was added to the reaction mixture, which was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1 - 10 / 1) to give compound 2-7 (2.4 g, 2.65 mmol, 76% yield). The molecular formula of compound 2-7 is: C 47 H 59 O 15 N3, molecular weight: 905.3, LC-MS measured value: 904.4 (MH). 1 H NMR (400 MHz, CDCl3): δ7.30 (dd, J = 4.2, 1.9 Hz, 1H), 7.29-7.25 (m, 5H), 7.19-7.15 (m, 4H), 6.85-6.81 (m, 4H), 5.40-5.34 (m, 1H), 5.30 (s, 1H), 5.26 -5.19 (m, 1H), 5.13 (ddd, J = 14.5, 10.9, 3.3 Hz, 1H), 4.85 - 4.78 (m, 1H), 4.75 - 4.71 (m, 1H), 4.68 - 4.61 (m, 1H), 4.50 (d, J = 11.5 Hz, 1H), 4.18 - 4.11 (m, 2H), 4.06 - 3.97 (m, 1H), 3.90 (dt, J = 10.6, 6.8 Hz, 2H), 3.80 (s, 6H), 3.67 - 3.46 (m, 4H), 3.25 - 3.19 (m, 2H), 2.34 - 2.23 (m, 1H), 2.17 - 2.15 (m, 3H), 2.10 - 2.03 (m, 5H), 1.98 (dt, J = 12.9, 2.4 Hz, 4H), 1.76 - 1.61 (m, 4H), 1.37 (t, J = 7.3 Hz, 3H).

[0071] 2.8 Preparation of Compound I-1-7 [ka] Compound 2-7 (2.65 mmol, 2.4 g) was placed in a clean, dry reaction flask and 50 mL of anhydrous dichloromethane (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) was added. At room temperature, under argon protection, 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphorodiamidite (2.0 equiv, 5.3 mmol, 1.6 g) and 4,5-dicyanoimidazole (1.5 equiv, 3.97 mmol, 470.0 mg) were added and the mixture was stirred at room temperature for 1 hour. After the reaction, 50 mL of dichloromethane was added to the reaction mixture. of dichloromethane was added and washed with 100 mL of saturated sodium bicarbonate solution. The organic phase was dried, filtered and concentrated, and the resulting crude product was 18 Reversed-phase column (specification: 30 μm; The compound I-1-7 was purified using a commercially available solvent (MeCN:HO = 75%:25%) (100 A, commercially available, purchased from Shanghai Borun Biotechnology Co., Ltd.) to give a white solid, I-1-7 (2.03 g, 1.84 mmol, 70% yield). The molecular formula of compound I-1-7 is: C 56 H 76 O 15N6P, molecular weight: 1105.5, LC-MS observed value: 1128.4 (M+Na). 1 H NMR (400 MHz, DMSO-d6): δ8.12-8.06 (m, 1H), 7.78 (dd, J = 9.1, 2.0 Hz, 1H), 7.35-7.28 (m, 4H), 7.23 - 7.17 (m, 5H), 6.88 (d, J = 7.5 Hz, 4H), 5.21 (d, J = 3.3 Hz, 1H), 4.97 (dd, J = 11.2, 3.0 Hz, 1H), 4.86 - 4.75 (m, 1H), 4.52 (s, 1H), 4.47 (d, J = 8.5 Hz, 1H), 4.04 - 3.98 (m, 3H), 3.91 - 3.83 (m, 1H), 3.74 (s, 6H), 3.70 - 3.60 (m, 3H), 3.58 - 3.47 (m, 3H), 3.39 (t, J = 11.7 Hz, 2H), 3.31 (d, J = 4.1 Hz, 1H), 3.19 (qd, J = 8.7, 3.8 Hz, 1H), 3.02 (dt, J = 19.9, 6.8 Hz, 1H), 2.78 - 2.70 (m, 1H), 2.60 (td, J = 5.8, 1.8 Hz, 1H), 2.09 (s, 5H), 1.98 (s, 4H), 1.89 (s, 3H), 1.73 (s, 3H), 1.44 (s, 4H), 1.20 - 0.88 (m, 14H). 31 P NMR (162 MHz, DMSO-d6): δ 148.22 (s), 146.82 (t, J = 35.8 Hz).

[0072] 2. Preparation of siRNA conjugates Using the solid-phase phosphoramidite method, compound SA51 prepared above was used as the starting cycle, and nucleoside monomers were linked one by one in the 3'→5' direction in the order of the nucleotide sequence. Linking each nucleoside monomer involves four steps: deprotection, coupling, capping, and oxidation or sulfurization. The same synthesis conditions were used for the sense and antisense strands.

[0073] Equipment model: Biolytic Dr. Oligo 48 solid phase synthesis system, Biolytic Embed CPG Frits universal synthesis column DS0200, Biolytic 96-well plate desalting column DC 189650 (80 mg). Table 1 shows the reagents used in the synthesis of the siRNA conjugates. [Table 1] The synthesis conditions were as follows:

[0074] The nucleoside monomer was supplied as a 0.05 M solution in acetonitrile, and the deprotection reaction conditions in each step were the same: temperature 25°C, reaction time 3 minutes, deprotection reagent DCA, and injection volume 180 μL.

[0075] The coupling reaction conditions for each step were the same: temperature 25°C, reaction time 3 min, nucleoside monomer injection volume 90 μL, catalyst ACT injection volume 110 μL.

[0076] The capping conditions for each step were the same: a temperature of 25°C and a reaction time of 2 minutes. The capping reagent solution was a 1:1 molar mixture of CapA and CapB (CapB1:CapB2 = 1:1). The injection volume of the capping reagent was 180 μL.

[0077] The oxidation reaction conditions for each step were the same: temperature 25°C, reaction time 3 minutes, and injection amount of the oxidation reagent OXD 180 μL.

[0078] The sulfurization reaction conditions for each step were the same: temperature 25°C, reaction time 4 min, sulfurization reagent 0.05 The sulfurization reagent was a solution of PADS in pyridine and acetonitrile. The injection volume of the sulfurization reagent was 180 μL.

[0079] After the final nucleoside monomer was linked, the nucleic acid sequence linked to the solid support was sequentially cleaved, deprotected, purified, desalted, and then lyophilized to obtain the sense and antisense strands. The cleavage and deprotection conditions were as follows: a 3:1 mixture of aqueous ammonia and ethanol was added to the synthesized nucleotide sequence linked to the support, bringing the volume to 0.8 mL. The reaction was allowed to proceed at 50°C for 15 hours, followed by filtration to remove the remaining support, and the supernatant was concentrated to dryness under vacuum.

[0080] The purification and desalting conditions were as follows: 18 Desalting is performed using a reversed-phase chromatography column. The specific conditions are as follows: (1) Sample preparation Add 0.1 M TEAA (triethylamine acetate) to the oligonucleotide sample up to a volume of 0.8 mL. (2) Activation of 96-well plates Activation: 0.8 mL of acetonitrile is passed through each well of a 96-well plate for activation. Equilibration: Equilibrate a 96-well plate with 0.8 mL of TEAA (pH 7.0) solution. (3) The refining process involves the following steps in sequence: 0.8 mL of the solution containing the oligonucleotide is passed through a desalting column. Wash the 96-well plate twice with 0.8 mL of 6.5% ammonia water to remove failed sequences. Wash the 96-well plate twice with 0.8 mL of deionized water to remove salt. Wash the 96-well plate three times with 0.8 mL of 3% trifluoroacetic acid to remove DMT and observe that the adsorbed layer turns orange-red. Wash the 96-well plate with 0.8 mL of 0.1 M TEAA. Wash the 96-well plate twice with 0.8 mL of deionized water to remove trifluoroacetic acid and any remaining salts. Elute with 0.6 mL of 20% acetonitrile, collect and lyophilize. The detection method was as follows: Waters Acquity UPLC-LTQ LCMS (column: ACQUITY UPLC BEH C 18 ) to detect the purity of the sense and antisense strands and analyze their molecular weights. If the measured values ​​match the theoretical values, the synthesized sense and antisense strands have a base group conjugated to the 3'-end and / or 5'-end. Indicates that there is something.

[0081] The annealing procedure is as follows: Dissolve the sense and antisense strands synthesized in step 2 in water for injection to prepare 0.1 mg / mL to 40 mg / mL solutions. Determine the equimolar ratio using a densitometer, mix them, heat to 90°C for 5 minutes, then slowly cool. Allow them to form a double-stranded structure via hydrogen bonding. Samples are collected and the SEC purity of the product is determined. The double-stranded sample is then lyophilized. Example 3

[0082] Synthesis of Ago, Cgo, and Ugo monomers and preparation of siRNA containing these monomer modifications 3.1. The synthesis route of Ago monomer is described in Example 2 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows: [ka]

[0083] (1) Anhydrous diisopropylamine (16.2 g, 160.0 mmol, 22.6 mL, 2.0 equiv) was dissolved in 350 mL of anhydrous tetrahydrofuran, cooled to -70°C to -78°C, and protected with nitrogen. A solution of n-butyllithium (2.5 M, 67.1 mL) was added dropwise (slowly over 10 minutes). The reaction mixture was stirred at -70°C to -78°C for 30 minutes. Compound 1 (9.44 g, 79.9 mmol, 9.17 mL, 1.0 equiv) was dissolved in 175 mL of anhydrous tetrahydrofuran, cooled to -70°C to -78°C, and the solution obtained in the previous step was added dropwise (slowly over 10 minutes). The reaction mixture was stirred at -70°C to -78°C for 30 minutes. While maintaining the previous temperature, hexamethylphosphoric triamide (26.1 g, 146 mmol, 25.6 mL, 1.82 equiv) and benzyl chloromethyl ether (17.5 g, 112 mmol, 15.5 mL, 1.4 equiv) were slowly added dropwise to the previous reaction mixture (slow addition, addition time: at least 10 minutes). After the addition was completed, the mixture was warmed to 0°C and stirred for 3 hours. TLC and LCMS confirmed the disappearance of compound 1. 600 The reaction was quenched with 200 mL of saturated ammonium chloride solution, and the mixture was extracted with 200 mL of methyl tert-butyl ether. The organic phase was collected, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 1 / 1) to give pale brown compound 2 (9.69 g, 40.7 mmol, 51% yield). 1 H NMR (400 MHz, CDCl3): δ 7.46-7.28 (m, 10H), 4.58-4.46 (m,2H), 4.19-4.08 (m, 1H), 3.82-3.67 (m, 5H), 2.77 (q, J = 6.1 Hz, 1H), 1.24 (d, J = 6.5 Hz, 4H). LC-MS:C 13 H 18O4, molecular weight 238.1, 239.1 (M+H).

[0084] (2) Compound 2 (14.7 g, 61.7 mmol, 1.0 equiv) was added to 150 The resulting mixture was dissolved in 1 mL of dichloromethane and, under nitrogen protection, added with imidazole (16.8 g, 247.0 mmol, 4.0 equiv) and tert-butyldimethylchlorosilane (27.9 g, 185.0 mmol, 22.7 mL, 3.0 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 hour, and the disappearance of compound 2 was confirmed by TLC and LCMS. 100 mL of dichloromethane was added to the reaction mixture, and the mixture was washed twice with 400 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to give compound 3 (12.0 g, 34.0 mmol, 55% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 7.40-7.25 (m, 5H), 4.52 (d, J = 2.4Hz, 2H), 4.10 (t, J = 6.3 Hz, 1H), 3.75-3.65 (m, 4H), 3.59 (dd, J = 9.2,5.3 Hz, 1H), 2.79 (dt, J = 8.4, 5.9 Hz, 1H), 1.17 (d, J = 6.2 Hz, 3H), 0.86(s, 9H), 0.04 (d, J = 8.6 Hz, 6H). LC-MS:C 19 H 32 O4Si, molecular weight 352.1, 353.2 (M+H).

[0085] (3) Compound 3 (11.1 g, 31.5 mmol, 1.0 equiv) was dissolved in tetrahydrofuran and cooled to between -70 and -60 °C. Diisobutylaluminum hydride (1.0 M, 69.3 mL, 2.2 equiv) was added dropwise under nitrogen protection. Stirring was continued at this temperature for 2 h. After confirming the disappearance of compound 3 by LCMS, the temperature was raised to 0 °C, 20 mL of ethyl acetate was added, and the reaction was quenched with 100 mL of potassium sodium tartrate solution. Stirring was continued for 30 min. The mixture was washed with 100 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 4 (9.75 g, 30.0 mmol, 95% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 7.40-7.27 (m, 5H), 4.59-4.45 (m, 2H), 4.19 (dd, J = 6.2, 3.7 Hz, 1H), 4.01 (dd, J = 11.3, 4.0 Hz, 1H),3.78-3.60 (m, 3H), 1.78-1.68 (m, 1H), 1.29-1.21 (m, 3H), 0.95-0.87 (m,9H), 0.12-0.02 (m, 6H). LC-MS:C 18 H 32 O3Si, molecular weight 324.1, 325.2 (M+H).

[0086] (4) Compound 4 (9.75 g, 30.0 mmol, 1.0 equiv) was dissolved in tetrahydrofuran and cooled to 0°C. Under nitrogen protection, p-toluenesulfonyl chloride (11.5 g, 60.1 mmol, 2.0 equiv) and methylimidazole (6.17 g, 75.1 mmol, 5.99 mL, 2.5 equiv) were added dropwise. After the addition was complete, the mixture was warmed to room temperature and stirred for 16 hours. LCMS confirmed the disappearance of compound 4. 20 mL of ethyl acetate was added to the reaction mixture, and the reaction was quenched with 100 mL of potassium sodium tartrate solution in an ice bath and stirred for 30 minutes. This mixture was then diluted with 100 mL of saturated brine. After washing with ethyl acetate, the mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product of compound 5 (13.7 g, 28.6 mmol, 95% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 7.89-7.68 (m, 2H), 7.42-7.17 (m,10H), 4.47-4.33 (m, 2H), 4.23 (dd, J = 9.6, 5.1 Hz, 1H), 4.13-4.06 (m,1H), 4.01-3.94 (m, 1H), 3.52-3.34 (m, 2H), 2.43 (s, 3H), 2.02-1.89 (m,1H), 1.10 (d, J = 6.3 Hz, 3H), 0.81 (s, 8H), 0.04--0.05 (m, 6H). LC-MS:C 25 H 38 O5SSi, molecular weight 478.1, 479.2 (M+H).

[0087] (5) Under nitrogen protection, compound 5 (13.7 g, 28.6 mmol, 1.0 equiv) and 35 mL of acetonitrile were added to a dry reaction flask. The acetonitrile was evaporated at 35–40 °C to remove water from compound 5. Under nitrogen protection, 80 mL of N,N-dimethylformamide, compound 5-1 (9H-purin-6-amine) (4.25 g, 31.5 mmol, 1.1 equiv), and potassium carbonate (3.96 g, 28.6 mmol, 1.0 equiv) were added to a separate clean, dry reaction flask. The mixture was heated to 95–100 °C and stirred for 30 min. At this temperature, a solution of compound 5 (13.7 g, 28.6 mmol, 1.0 equiv) in N,N-dimethylformamide (60 mL) was added dropwise to the reaction mixture, and stirring was continued for 12 h. The disappearance of compound 5 was confirmed by LCMS, and the reaction mixture was cooled to room temperature. 200 mL of ethyl acetate was added. This mixture was washed successively with 200 mL of sodium bicarbonate solution and 100 mL of saturated saline. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The resulting crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give compound 6 (6.2 g, 14.0 mmol, 49% yield) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3): δ 8.37 (s, 1H), 7.75 (s, 1H), 7.39-7.24 (m, 6H), 5.66 (br, s, 2H), 4.47-4.34 (m, 3H), 4.21 (dd, J = 14.1, 8.8 Hz, 1H), 4.07 (dd, J = 6.2, 4.9 Hz, 1H), 3.42-3.34 (m, 2H), 2.10-1.96 (m, 1H),1.19 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.06 (d, J = 6.0 Hz, 6H). LC-MS:C 23 H 35 N5O2Si, molecular weight 441.1, 442.3 (M+H).

[0088] (6) Palladium carbon (3.0 g, 10% purity) was dissolved in 25 mL of methanol at room temperature, and 25 mL of a methanol solution of compound 6 (5.2 g, 11.8 mmol, 1.0 equiv) and trifluoroacetic acid (134.0 mg, 1.18 mmol, 87.2 μL) were added. The reaction mixture was stirred under 50 psi of hydrogen pressure for 48 hours. LCMS confirmed the disappearance of compound 6. The reaction mixture was filtered and concentrated to give the crude product, compound 7 (3.9 g, 11.1 mmol), as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 8.21 (s, 1H), 8.12 (s, 1H), 4.50-4.36(m, 1H), 4.33-4.22 (m, 1H), 4.15-4.02 (m, 1H), 3.53 (d, J = 5.9 Hz, 2H),2.21-2.09 (m, 1H), 1.25 (d, J = 6.4 Hz, 3H), 0.88 (s, 9H), 0.05 (d, J = 3.1Hz, 6H). LC-MS:C 16 H 29 N5O2Si, molecular weight 351.1, 352.2 (M+1).

[0089] (7) Compound 7 (3.9 g, 11.1 mmol, 1.0 equiv) was placed in a clean, dry reaction flask, and 10 mL of pyridine was added under nitrogen protection. The temperature was raised to evaporate the pyridine. This procedure was repeated once more to remove the water content of compound 7. 28 mL of pyridine was added, and trimethylchlorosilane (4.8 g, 44.4 mmol, The mixture was heated to room temperature and stirred for 2 hours. After confirming the disappearance of compound 7 by TLC, benzoyl chloride (6.2 g, 44.4 mmol, 5.15 mL, 4.0 equiv) was added in an ice bath and stirred for 2 hours. After confirming the disappearance of the starting material by TLC, 60 mL of water and 90 mL of concentrated aqueous ammonia were added dropwise and the mixture was stirred for 30 minutes. The reaction mixture was extracted with 250 mL of ethyl acetate. The organic phase was washed with saturated brine, dried, filtered, and concentrated. The resulting crude product was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1 to 10 / 1) to give compound 8 (4.0 g, 8.78 mmol, 79% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 9.22-8.90 (m, 1H), 8.79 (s, 1H),8.07-8.04 (m, 2H), 8.03 (d, J = 1.4 Hz, 1H), 7.65-7.59 (m, 1H), 7.57-7.50 (m, 2H), 4.62-4.50 (m, 1H), 4.42 (dd, J = 14.3, 8.6 Hz, 1H), 4.24-4.09 (m,1H), 4.05 (d, J = 6.3 Hz, 1H), 3.59-3.48 (m, 1H), 3.47-3.35 (m, 1H),2.04-1.98 (m, 1H), 1.31 (d, J = 6.3 Hz, 3H), 0.98-0.84 (m, 9H), 0.11 (d, J= 10.1 Hz, 5H). LC-MS:C 23 H 33 N5O3Si, molecular weight 455.2, 456.3 (M+H).

[0090] (8) Compound 8 (4.0 g, 8.78 mmol, 1.0 equiv) was placed in a clean, dry reaction flask and, under nitrogen protection, 10 mL of pyridine was added. The mixture was heated to evaporate the pyridine. This procedure was repeated once more to remove the water content of compound 8. 28 mL of pyridine was added, and 4,4'-dimethoxytrityl chloride (3.27 g, 9.66 mmol, 1.1 equiv) was added in an ice bath. The mixture was heated to room temperature and stirred for 1 hour. After confirming the disappearance of compound 8 by TLC, 150 mL of ethyl acetate was added to the reaction mixture, which was washed with 200 mL of sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and the filtrate was concentrated. The resulting crude product was purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give compound 9 (5.91 g, 7.8 mmol, 88% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3): δ 9.07 (br s, 1H), 8.82 (s, 1H), 8.04 (d,J = 7.1 Hz, 2H), 7.80 (s, 1H), 7.65-7.58 (m, 1H), 7.57-7.50 (m, 2H),7.28-7.13 (m, 9H), 6.81-6.69 (m, 4H), 4.52-4.43 (m, 1H), 4.25 (dd, J =14.2, 8.6 Hz, 1H), 4.07 (dd, J = 6.3, 4.2 Hz, 1H), 3.76 (d, J = 4.5 Hz, 6H),3.22 (dd, J = 9.8, 5.4 Hz, 1H), 3.04 (dd, J = 9.8, 6.1 Hz, 1H), 2.34 (dd, J= 8.1, 4.5 Hz, 1H), 1.19 (d, J = 6.3 Hz, 3H), 0.90-0.77 (m, 9H), 0.07--0.09(m, 6H). LC-MS: C 44 H 51 N5O5Si, molecular weight 757.3, 758.4 (M+H).

[0091] (9) Compound 9 (3.00 g, 3.96 mmol, 1.0 equiv) was dissolved in tetrahydrofuran and then added to hydrogen fluoride pyridine salt (2.26 g, 79.2 mmol, 2.1 mL, 20.0 equiv) and imidazole (10.8 g, To the mixture was added 158.0 mmol, 40.0 equiv). The mixture was warmed to room temperature and stirred for 2 hours. The disappearance of compound 9 was confirmed by LCMS. 50 mL of ethyl acetate was added, and the mixture was washed with 100 mL of sodium bicarbonate solution and 50 mL of saturated saline, dried, and then filtered. The filtrate was concentrated, and the resulting crude product was purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give compound 10 (2.44 g, 3.79 mmol, 96% yield) as a pale yellow oil. 1 H NMR (400 MHz, DMSO-d6): δ 11.16 (br s, 1H), 8.70 (s, 1H), 8.33 (s, 1H), 8.05 (d, J = 7.4 Hz, 2H), 7.69-7.61 (m, 1H), 7.60-7.52 (m,2H), 7.25-7.12 (m, 5H), 7.05 (t, J = 8.9 Hz, 4H), 6.78 (dd, J = 8.9, 3.1 Hz,4H), 4.79 (d, J = 4.0 Hz, 1H), 4.51-4.28 (m, 2H), 3.81 (d, J = 4.0 Hz, 1H), 3.70 (s, 6H), 3.10 (dd, J = 9.8, 4.9 Hz, 1H), 2.89 (dd, J = 9.7, 5.1 Hz, 1H),2.37-2.23 (m, 1H), 1.03 (d, J = 6.3 Hz, 3H). LC-MS:C 38 H 37 N5O5, molecular weight 643.2, 644.2 (M+H).

[0092] (10) Compound 10 (1.5 g, 2.33 mmol, 1.0 equiv) was placed in a clean, dry reaction flask, and 4 mL of acetonitrile was added under nitrogen protection. The temperature was raised to 35-40 °C to evaporate the acetonitrile. This procedure was repeated once more to remove the water content of compound 10. At room temperature, 15 mL of anhydrous dichloromethane was added to the reaction flask. Compound 11-1 (1.05 g, 3.5 mmol, 1.11 mL, 1.5 equiv) and 4,5-dicyanoimidazole (358 mg, 3.03 mmol, 1.3 equiv) was added and stirring was continued at room temperature for 1 hour. The disappearance of compound 10 was confirmed by TLC. 30 mL of dichloromethane was added, and the mixture was washed with sodium bicarbonate solution (50 mL x 2) and saturated saline solution (50 mL). The organic phase was dried, filtered, and the filtrate was concentrated. The obtained crude product was dissolved in 50 mL of methyl tert-butyl ether, and 100 mL of 1% aqueous sodium hydroxide solution was added and stirred for 30 minutes. The organic phase was left to stand and collected. The organic phase was washed with saturated saline solution, dried, filtered, and concentrated. The crude product was obtained by C 18 Preparative purification using a reverse phase column gave the pale yellow product SA000001 (1.1 g, 1.3 mmol, 56% yield). 1 H NMR (400 MHz, CD3CN): δ 9.33 (br s, 1H), 8.61 (br s, 1H), 7.99 (d, J = 11.0 Hz, 3H), 7.67-7.60 (m, 1H), 7.59-7.49 (m, 2H),7.32-6.99 (m, 9H), 6.75 (td, J = 9.2, 6.5 Hz, 4H), 4.50-4.38 (m, 1H),4.36-4.13 (m, 2H), 3.72 (dd, J = 4.8, 1.5 Hz, 6H), 3.66-3.45 (m, 3H), 3.25(td, J = 9.6, 5.4 Hz, 1H), 3.01 (ddd, J = 17.9, 10.0, 5.8 Hz, 1H), 2.62 (t, J= 5.9 Hz, 1H), 2.53 (t, J = 5.9 Hz, 1H), 1.32-1.22 (m, 4H), 1.17-1.05 (m, 12H). 31 P NMR (DMSO-d6, 162 MHz): δ ppm 147.7, 146.8. LCMS: C 47 H 54 N7O6P, molecular weight 843.3, 844.5 (M+H).

[0093] 3.2. The synthesis route of Cgo monomer is described in Example 4 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows: [ka]

[0094] (1) Compound 3-2 (8.5 g, 20.3 mmol, prepared in Example 5) and 1,2,4-triazole (19.5 g, 282.0 mmol, 13.9 equiv) were dissolved in pyridine (128.0 mL) at room temperature. 4-Chlorophenyl dichlorophosphate (56.9 mmol, 9.25 mL, 2.8 equiv) was then added dropwise to the reaction mixture in an ice-water bath. The reaction mixture was stirred at 30°C for 16 hours. After completion of the reaction, the pyridine solvent was removed by vacuum distillation. The remaining mixture was extracted three times with water and ethyl acetate. The combined organic phases were dried in a rotary swirl to obtain a yellow oily crude product, compound C-1 (9.5 g), which was used directly in the next reaction. Mass spectrometry identification of compound C-1 (C 24 H 35 N5O3Si, molecular weight 469.1, [M+H] = 470.3).

[0095] (2) Compound C-1 (9.5 g, 20.2 mmol) was dissolved in 1,4-dioxane (95.0 mL) at room temperature, and then aqueous ammonia (1.38 mol, 212.1 mL, 25% purity, 68.0 equiv) was added to the reaction mixture. The reaction mixture was stirred at 30°C for 16 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the remaining mixture was extracted three times with water and dichloromethane. The combined organic phases were dried in a rotary sieve to obtain a yellow solid crude product, compound C-2 (8.5 g), which was used directly in the next reaction. Mass spectrometry identification of compound C-2 (C 22 H 35 N3O3Si, molecular weight 417.1, [M+H] = 418.2).

[0096] (3) Compound C-2 (8.5 g, 20.2 mmol) was dissolved in N,N-dimethylformamide (85.0 mL) at room temperature, and then acetic anhydride (3.1 g, 30.4 mmol, 2.85 mL, 1.5 equiv) was slowly added to the reaction mixture. The reaction mixture was stirred at 30°C for 3 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the remaining mixture was extracted three times with saturated sodium bicarbonate solution and ethyl acetate. The combined organic phases were dried in a rotary sieve. The resulting crude product was purified by silica gel column chromatography (dichloromethane / methanol 1:0 to 100:1) to obtain yellow solid compound C-3 (4.2 g, reaction yield 43%). 1 H NMR data: (400 MHz, DMSO-d) δ 10.7 (s, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.29 (m, 5H), 7.08 (d, J = 7.2 Hz, 1H), 4.36 (d, J= 1.2 Hz, 2H), 4.05-3.99 (m, 2H), 3.72-3.67 (m, 1H), 3.39 (dd, J = 6.4 Hz,2H), 2.15-2.08 (m, 1H), 2.08 (s, 3H), 1.15 (d, J = 6.4 Hz, 3H), 0.85 (s,9H), 0.02 (d, J = 6.8 Hz, 6H). Compound C-3 Mass spectrometric identification of (C 24 H37 N3O4Si, molecular weight 459.1, [M+H] = 460.2).

[0097] (4) Compound C-3 (4.3 g, 9.35 mmol) was dissolved in dichloromethane (46.0 mL) at −78°C, and then boron trichloride (1.0 M in DCM, 46.8 mL, 5.0 equiv) was slowly added to the reaction mixture. The reaction mixture was then stirred at −78°C for 4 hours. After completion of the reaction, the reaction mixture was quenched with triethylamine (40.0 mL) and methanol (88.0 mL). The remaining mixture was extracted three times with water and dichloromethane. The combined organic phases were dried in a rotary evaporator, and the resulting crude product was purified by C 18 The product was purified using a reverse phase column to obtain a white solid compound C-4 (0.96 g, reaction yield 40%). 1 H NMR data: (400 MHz, DMSO-d6)δ 10.7 (s, 1H), 8.01 (d, J = 7.2 Hz, 1H), 7.12 (d, J = 7.2 Hz, 1H), 4.60 (d, J = 4.8 Hz, 2H), 4.53-4.50 (m, 1H), 4.00-3.99 (m, 1H), 3.75-3.70 (m, 2H), 3.37-3.32(m, 2H), 2.08 (s, 3H), 1.81-1.77 (m, 1H), 1.01 (d, J = 6.4 Hz, 3H). Mass spectrometry identification of compound C-4 (C 11 H 17 N3O4, molecular weight 255.1, [M+H] = 256.2).

[0098] (5) Compound C-4 (1.5 g, 5.88 mmol) was dissolved in pyridine (10.0 mL) at room temperature, and 4,4'-dimethoxytrityl chloride (2.4 g, 7.05 mmol, 1.2 equiv) was added to the reaction mixture in an ice-water bath. The reaction mixture was then stirred at room temperature for 4 hours. After completion of the reaction, the pyridine solvent was removed by distillation under reduced pressure, and the remaining mixture was extracted three times with saturated sodium bicarbonate solution and ethyl acetate. The combined organic phases were dried in a rotary evaporator. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate 4:1 to 0:1) to obtain a white solid, compound C-5 (0.7 g, reaction yield 70%). 1 H NMR data: (400 MHz, CDCl3)δ 9.71 (s, 1H), 7.39(d, J = 7.3 Hz, 3H), 7.35-7.21 (m, 7H), 7.06 (d, J = 7.1 Hz, 1H), 6.85 (d,J = 8.8 Hz, 4H), 4.71 (d, J = 3.3 Hz, 1H), 4.43 (dd, J = 13.8, 4.5 Hz, 1H),4.23-3.99 (m, 2H), 3.80 (s, 6H), 3.50-3.38 (m, 1H), 3.31 (dd, J = 10.0, 4.1Hz, 1H), 2.69 (t, J = 9.4 Hz, 1H), 2.21 (s, 3H), 1.08 (d, J = 6.1 Hz, 3H). Mass spectrometry identification of compound C-5 (C 32 H 35 N3O6, molecular weight 557.1, [M+H] = 558.4).

[0099] (6) Compound C-5 (2.0 g, 3.59 mmol) was dissolved in dichloromethane (20 mL) under nitrogen atmosphere at room temperature. 4,5-dicyanoimidazole (466 mg, 3.95 mmol, 1.1 equiv) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.4 g, 4.66 mmol, 1.48 mL, 1.3 equiv) were added to the reaction mixture. The mixture was then stirred at room temperature for 2 hours. After completion of the reaction, the mixture was dissolved in methyl tert-butyl ether (10 mL) and 1% sodium hydroxide solution (10 mL) and stirred at room temperature for 0.5 hours. The remaining mixture was extracted three times with saturated sodium bicarbonate solution and dichloromethane. The combined organic phases were dried in a rotary evaporator. The resulting crude product was purified by C. 18 The product was purified using a reverse phase column to obtain a white solid compound SA000015 (1.5 g, reaction yield 55%). 1 H NMR data: (400 MHz, CD3CN)δ 9.15 (s, 1H), 7.50-7.18 (m, 11H), 6.84-6.80 (m, 4H), 4.22-4.08 (m, 2H), 3.75-3.22(m, 11H), 3.23-3.22 (m, 2H), 2.62-2.51 (m, 2H), 2.38-2.35 (m, 1H), 2.12(s , 3H), 1.022-1.07 (m, 15H). 31 P NMR data: (400 MHz, CDCN) δ 147.5, 146.7. Mass spectrometric identification of compound SA000015 (C 41 H 52 N5O7P, molecular weight 757.1, [M+H] = 758.5).

[0100] 3.3. The synthesis route of Ugo monomer is described in Example 5 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows: [ka]

[0101] (1) Compound 1-4 (9.99 g, 30.8 mmol), compound U-1 (commercially available, purchased from Shanghai Haohong Biopharmaceutical Technology Co., Ltd.) (9.33 g, 43.1 mmol, 1.4 equiv), and triphenylphosphine (16.6 g, 63.2 mmol, 2.0 equiv) were dissolved in dry tetrahydrofuran (350.0 mL) under ice-water bath conditions. Diisopropyl azodicarboxylate (13.1 g, 64.7 mmol, 12.6 mL, 2.1 equiv) was then added dropwise to the reaction mixture. The reaction mixture was then stirred at room temperature for 2 hours. After completion of the reaction, the mixture was extracted three times with saturated sodium bicarbonate solution and ethyl acetate. The combined organic phases were dried in a rotary evaporator. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate 10:1 to 8:1) to obtain compound 3-1 (16.1 g, 99% yield) as a white solid. Compound 3-1 1 H NMR data: (400 MHz, DMSO-d6)δ 7.89-7.74 (m, 4H), 7.56-7.53 (m, 2H), 7.33-7.29 (m, 5H), 5.80-5.73 (m, 1H), 4.46-4.38(m, 2H), 4.00-3.91 (m, 2H), 3.60-3.50 (m, 1H), 3.49-3.43 (m, 2H)2.17-1.98 (m, 1H), 1.13 (s, 3H), 0.83 (s, 9H), 0.01 (d, J = 6.0 Hz, 6H). Mass spectrometry identification of compound 3-1 (C 29 H 38 N2O5Si, molecular weight 522.1, [M+H] = 523.2).

[0102] (2) Compound 3-1 (8.05 g, 15.4 mmol) was dissolved in methanol (160.0 mL) at room temperature, and then sodium methoxide (2.77 g, 15.4 mmol, 30% purity, 1.0 equiv) was slowly added to the reaction mixture. The reaction mixture was then stirred at room temperature for 12 hours. After completion of the reaction, the solvent methanol was removed by distillation under reduced pressure, and the remaining mixture was extracted three times with 1 M hydrochloric acid solution and ethyl acetate. The organic phases were combined and dried in a rotary evaporator. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate 1 The compound 3-2 was separated and purified using a 2:1 to 0:1 mixture, to obtain a white solid compound 3-2 (6.1 g, reaction yield 94%). 1 H NMR data: (400 MHz, DMSO-d6)δ 11.1 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.30-7.24 (m, 5H), 5.47-5.44 (m, 1H), 4.45-4.35(m, 2H), 3.98-3.94 (m, 1H), 3.79-3.78 (m, 1H), 3.63-3.57 (m, 1H),3.38-3.35 (m, 2H), 2.04-1.95 (m, 1H), 1.10 (s, 3H), 0.83 (s, 9H), 0.01 (d,J = 6.0 Hz, 6H). Mass spectrometry identification of compound 3-2 (C 22 H 34 N2O4Si, molecular weight 418.1, [M+H] = 418.2).

[0103] (3) Compound 3-2 (4.0 g, 9.56 mmol) was dissolved in dichloromethane (30.0 mL) at -70°C, and then boron trichloride (1.0 M in DCM, 66.9 mL, 7.0 equiv) was slowly added to the reaction mixture. The reaction mixture was then stirred at -70°C for 3 hours. After completion of the reaction, the reaction mixture was quenched with triethylamine (5.0 mL) and methanol (30.0 mL). The remaining mixture was extracted three times with water and dichloromethane. The combined organic phases were dried in a rotary evaporator, and the resulting crude product was purified by C 18 The product was purified by reverse phase column separation to obtain a white solid compound 3-3 (0.7 g, reaction yield 33%).1 H NMR data: (400 MHz, DMSO-d6)δ 7.54 (d, J = 8.0 Hz, 1H), 5.51 (d, J = 7.6 Hz, 1H), 3.88-3.84 (m, 1H), 3.72-3.70 (m,1H), 3.61-3.59 (m, 2H), 1.75-1.68 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H). Mass spectrometry identification of compound 3-3 (C9H 14 N2O4, molecular weight 214.1, [M+H] = 215.2).

[0104] (4) Compound 3-1 (0.4 g, 1.87 mmol) was dissolved in pyridine (4.0 mL) at room temperature, and 4,4'-dimethoxytrityl chloride (949.0 mg, 2.8 mmol, 1.5 equiv) was added to the reaction mixture in an ice-water bath. The reaction mixture was then stirred at room temperature for 2 hours. After completion of the reaction, the pyridine solvent was removed by distillation under reduced pressure, and the remaining mixture was extracted three times with saturated sodium bicarbonate solution and ethyl acetate. The combined organic phases were dried in a rotary evaporator. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate 4:1 to 0:1) to obtain a white solid compound 3-4 (0.7 g, reaction yield 70%). 1 H NMR data: (400 MHz, DMSO-d6)δ 11.3 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.33-7.29 (m, 4H), 7.20-7.17 (m, 5H), 6.86-6.83(m, 4H), 5.40 (d, J = 8.0 Hz, 1H), 4.61 (d, J = 4.8 Hz, 2H), 3.83-3.79 (m,2H), 3.72 (s, 6H), 3.71-3.68 (m, 1H), 3.08-2.90 (m, 2H), 1.90 (s, 1H), 1.01 (d, J = 6.4 Hz, 3H). Mass spectrometry identification of compound 3-4 (C 30 H 32 N2O6, molecular weight 516.1, [M+H] = 517.4).

[0105] (5) Compound 3-4 (1.2 g, 2.32 mmol) was dissolved in dichloromethane (12.0 mL) at room temperature under nitrogen atmosphere. 4,5-dicyanoimidazole (357.0 mg, 3.02 mmol, 1.3 equiv) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.05 g, 3.48 mmol, 1.5 equiv) were added to the reaction mixture. The mixture was then stirred at room temperature for 2 hours. After completion of the reaction, the mixture was dissolved in methyl tert-butyl ether (10.0 mL) and 1% sodium hydroxide solution (10.0 mL) and stirred at room temperature for 0.5 hours. The remaining mixture was extracted three times with ethyl acetate. The combined organic phases were dried in a rotary evaporator, and the resulting crude product was purified by C. 18 The product was purified using a reverse phase column to obtain a white solid compound SA000016 (1.2 g, reaction yield 71%). 1 H NMR data: (400 MHz, CD3CN)δ 9.39 ( s,1H), 7.39-7.24 (m, 10H), 6.85-6.81 (m, 4H), 5.43-5.39 (m, 1H), 4.21-4.18(m, 1H), 3.86-3.77 (m, 1H), 3.75 (s, 6H), 3.56-3.53 (m, 5H), 3.28-3.05 (m,2H), 2.62-2.61 (m, 2H), 2.22-2.19 (m, 2H), 1.22-1.07 (m, 15H). 31 P NMR data: (400 MHz, CDCN) δ 147.6, 146.5. Mass spectrometric identification of compound SA000016 (C 39 H 49 N4O7P, molecular weight 716.1, [M+H]= 717.5).

[0106] 3.4 Preparation of modified siRNA

[0107] The 5' region of the antisense strand contained chemical modifications indicated by Ago, Cgo, or Ugo at nucleotide position 6 or 7. This modified siRNA was obtained with reference to the solid-phase synthesis in Example 2. The inventors previously designed and synthesized a number of PD-L1 siRNAs, and after testing their cellular activity, eliminated some PD-L1 siRNAs with low efficacy and retained PD-L1 siRNAs with relatively good activity for further experiments. The specific sequences are shown in Tables 2 to 4 below.

[0108] Table 2 below shows the unmodified sense and antisense strands of PD-L1 siRNA, Tables 3-1 and 3-2 show the modified sense and antisense strands of PD-L1 siRNA (the modified sequences of each siRNA in Table 1 are listed from top to bottom), and Table 4 shows the siRNA conjugate sequences. (Note: The capital letters A, C, G, and U represent adenosine 3'-phosphate, cytidine 3'-phosphate, guanosine 3'-phosphate, and uridine 3'-phosphate, respectively.) A lowercase letter m indicates that the nucleotide immediately to the left of the m is a 2'-methoxy-modified nucleotide. A lowercase letter f indicates that the nucleotide immediately to the left of the m is a 2'-fluoro-modified nucleotide. A lowercase s in the middle of the capital letter indicates that the two nucleotides immediately to the left of the s are linked by a phosphorothioate group. An s at the beginning of the 3' end indicates that the nucleotide immediately to the left of the s has a phosphorothioate group at the end. For the synthesis of SA51 and conjugates, see Example 2.) [Table 2] [Table 3-1] [Table 3-2] [Table 4] Example 4

[0109] IC50 In Vitro Screening: Dual-Glo® Dual-Luciferase Assay PD-1 was detected using the Dual-Glo® Dual-Luciferase Assay in vitro. The activity of L1-targeting siRNA was tested. The final concentration of siRNA in the initial transfection was 10 nM. Compounds that showed less than 35% residual activity at 10 nM were screened for activity at two concentrations: 1 nM and 0.2 nM. Priority compounds selected from the two concentration screenings were then screened for IC50.

[0110] 1) Cell culture and plasmid / siRNA co-transfection HEK293 cells were cultured in DMEM high glucose medium (Gibco, CA) containing 10% fetal bovine serum. 11995500 The cells were cultured in a BT (Biotin™) at 37°C and 5% CO2. When they reached approximately 90% confluence, they were digested with trypsin (Thermo, 25200072) and resuspended. The complete human PD-L1 reference sequence (NM_014143.4) was cloned into the XhoI and NotI multiple cloning sites of the dual luciferase psiCHECK2™ vector to construct the hs-psiCHECK plasmid. The dual luciferase plasmid and siRNA were transfected at 1x10 ng / ml using Lipofectamine™ 2000 Transfection Reagent (Thermo, 11668500). 4 Each well of a 96-well plate was transfected with 0.3 μL of Lipofectamine™ 2000 in 19.7 μL of Opti-MEM (Gibco, The mixture was added to a 96-well plate and incubated at room temperature for 15 minutes. Then, 80 μL of fresh DMEM high glucose medium (Gibco, CA) containing 10% fetal bovine serum was added. 11995500 The cells were resuspended in BT and added to the medium. The cells were incubated for 24 hours, and luciferase activity was measured (Ikseong Biotechnology, 11405ES80).

[0111] 2) Dual-Glo® Dual Luciferase Assay Twenty-four hours after siRNA transfection, dual luciferase (firefly luciferase as an internal control) and Renilla luciferase (PD-L1 target sequence inserted after PolyA and fused to a single mRNA) were measured. According to the product manual (Bioteck Biotechnology, 11405ES80), the luminescence signal of firefly luciferase was first detected using a multifunction plate reader (Bioteck, Synergy LX) followed by the luminescence signal of Renilla luciferase. The order of detection of Renilla luciferase on the microplate should be the same as that of firefly luciferase. The Renilla luciferase signal values ​​for each well were ratio-normalized to the firefly luciferase (control) signal, and then the activity of each siRNA was assessed by comparing it with cells transfected with the same plasmid but without siRNA treatment. All transfections were performed in duplicate.

[0112] The results are shown as the residual rate relative to the control group to which no siRNA was added (the control group is set at 100%), and the data are shown in Table 5. As can be seen from Table 5, the experimental results for each group, except for SD003798 and SD003955, were good, and further research was conducted on the siRNAs that showed good effects. [Table 5] Example 5

[0113] In vitro screening of siRNA activity and IC50 in SNU-387 cells IC50 in vitro screening was performed in SNU-387 cells at eight concentrations (10 nM to 3-fold dilutions, a total of eight concentration points). SNU-387 cells were cultured in RPMI-1640 medium (Thermo, 11875119) containing 10% fetal bovine serum at 37°C and 5% CO2, and then resuspended by trypsin digestion. 2x10 siRNAs were added using RNAiMAX (Thermo, 13778150). 40.3 μL of RNAiMAX was added to each well of a 96-well plate containing 19.7 μL of Opti-MEM (Gibco, 31985070) containing different concentrations of siRNA. The mixture was then added to the 96-well plate. After incubation at room temperature for 15 minutes, the mixture was added to the 96-well plate, followed by the addition of cells resuspended in 80 μL of fresh RPMI-1640 medium (Thermo, 11875119) containing 10% fetal bovine serum. The cells were incubated for 24 hours, and RNA was extracted using a tissue and cell extraction kit (Shio Biology, MNTR / FX96), reverse transcribed to cDNA (Takara, 6210B), and analyzed by SYBR Green qPCR (Vazyme, The expression level of the PD-L1 gene was measured using the Q711). For specific operating procedures, please refer to the respective instructions.

[0114] Primers and probes for the target gene PD-L1: Forward primer: TGCAGGGCATTCCAGAAAGAT (SEQ ID NO: 1) No. 29); Reverse primer: CCTTGGGAACCGTGACAGTA (SEQ ID NO. 30); Primers for the internal control gene β-Actin: Forward primer: TGCACCACCAACTGCTTAGC (SEQ ID NO. 31); Reverse primer: ACTGTGGTCATGAGTCCTTCCA (SEQ ID No. 32);

[0115] The relative levels at different concentrations compared to cells untreated with siRNA were calculated, and IC50 values ​​were calculated. The results are shown in Table 6 and Figure 1. The results showed that SD003141, SD003143, SD003187, SD003842, SD003844, and SD003887 had relatively good activity. [Table 6] Example 6

[0116] In vitro on-target and off-target evaluation of siRNAs containing different chemical modifications Dual luciferase reporter genes were used to detect the on-target and off-target activities of siRNAs with different chemical modifications.

[0117] HEK293 cells were cultured in DMEM high-sugar medium containing 10% fetal bovine serum at 37°C under 5% CO2. Cells were co-transfected with reporter gene plasmids and siRNAs at different concentrations (11 concentrations total, 3-fold dilutions starting from a final concentration of 90 nM) using Lipofectamine 2000 (ThermoFisher, 11668019) according to the manufacturer's instructions. 24 hours after transfection, detection was performed using a Dual Luciferase Detection Kit (Issei Bio, 11405ES80). The reporter plasmids contained two sequences: one that complemented the antisense strand (on-target reporter plasmid) and one that contained five tandem sequences matching positions 12-19 at the 5' end of the sense strand (off-target reporter plasmid). All reporter plasmids contained firefly luciferase, which served as an internal control. A control group was transfected with the plasmid alone. The Renilla luciferase signal value of each well was normalized to the firefly luciferase (control) signal, and then the relative levels at different concentrations were calculated compared to cells transfected with the same plasmid but not treated with siRNA, and the IC50 values ​​were calculated. The results are shown in Table 7. The results showed that for some sequences, modifying the 6th or 7th nucleotide in the 5' region of the antisense strand did not affect activity, while at the same time improving off-target effects and improving the safety of the siRNA. [Table 7] Example 7

[0118] In vivo activity of siRNA containing different chemical modifications in HDI mice In this example, we combined the in vitro on-target and off-target evaluation results to select siRNAs for conjugate synthesis and evaluate their in vivo activity in HDI mice. The siRNA conjugates were obtained by solid-phase synthesis according to Example 2.

[0119] At least 14 days before conjugate administration, 6-8 week old female Balb / C mice ( Humanized PD-L1-expressing mice were constructed in Zhejiang Weitong Lihua (Weitong University) by high-pressure tail vein injection. 2 μg of a plasmid containing PD-L1 mRNA was injected into the tail vein within 5–7 seconds to generate PD-L1-SEAP model mice (Zhang G et al., “High levels of foreign gene expression inhepatocytes after tail vein injection of naked plasmid DNA,” Human GeneTherapy 1999 Vol. 10, pp. 1735–1737). Inhibition of PD-L1 expression by PD-L1 siRNA conjugates resulted in the suppression of secretory alkaline phosphatase (SEAP) expression. Serum was collected by retroorbital bleed one day before administration. SEAP expression levels in serum were measured using the Phospha-Light SEAP Reporter Gene Assay System (Invitrogen) according to the manufacturer's instructions. Mice were grouped based on their mean SEAP levels. Mice in the experimental group received the conjugate subcutaneously, while mice in the vehicle group received phosphate-buffered saline (PBS). Each mouse received 3 mg / kg of the conjugate subcutaneously. Blood samples were collected again 7 and 28 days after administration, and serum was measured for SEAP expression levels using the Phospha-Light SEAP Reporter Gene Analysis System (Invitrogen) according to the manufacturer's instructions. The post-administration SEAP level for each animal was divided by the pre-administration SEAP level for that animal to determine a "normalized to pretreatment" expression ratio.

[0120] The results are shown in terms of the residual serum SEAP expression levels (vehicle group = 100%) in each group before and after administration. The relative residual expression levels are shown in Table 8 and Figure 2. At 7 days after administration, the conjugates SD004177, SD004178, SD004179, SD004240, SD004180, SD004241, SD004242, SD004181, and SD004182 showed good activity, with inhibition rates exceeding 80%. At 28 days after administration, the SD004178 and SD004180 compounds still maintained activity above 80%, demonstrating long-term efficacy. [Table 8]

[0121] In this example, the HDI model enables in vivo detection based on human PD-L1 gene levels, which can better predict the in vivo activity of human PD-L1 mRNA, providing more and more reliable experimental data for drug clinical trials and drug launch.

[0122] Example 8

[0123] In vivo efficacy of siRNA in hPD-1 / PD-L1 humanized mouse AAV-HBV (hepatitis B virus) model In this example, the in vivo efficacy of siRNA was evaluated in an hPD-1 / PD-L1 humanized mouse AAV-HBV model to test its anti-hepatitis B virus activity. The siRNA conjugate was obtained by solid-phase synthesis according to Example 2.

[0124] An hPD-1 / PD-L1 humanized mouse AAV-HBV model was established 6 weeks before conjugate administration. A persistent HBV infection mouse model was established by injecting rAAV8-1.3HBV into the tail vein of 6-8 week-old B6-hPD-1 / PD-L1 female mice. The AAV virus dose was 1E+11 vg / mouse. Six weeks after virus injection, blood was collected from the submandibular region of the animals and centrifuged at 5000 rpm at 4°C for 10 minutes. The serum was diluted with PBS, with the dilution factor determined based on the actual situation. The diluted samples were then sent to Beijing Di'an Medical Testing Laboratory Co., Ltd. for detection of HBsAg (hepatitis B surface antigen), and the results were back-calculated according to the dilution factor. HBsAg was quantified using direct electrochemiluminescence. The animals were divided into groups based on HBsAg levels, and on day 0, they were subcutaneously injected with 7.5 mg / kg body weight once a week. On day 49 of the experiment, blood samples were taken to detect HBsAg levels and evaluate the anti-hepatitis B virus activity of the siRNA.

[0125] The HBsAg reduction on day 49 after administration is shown in Table 9. The results showed that both SD004178 and SD004180 could significantly reduce HBsAg levels. [Table 9] Although the present invention has been described in detail above, the purpose is to enable those skilled in the art to understand and practice the contents of the present invention, and not to limit the protection scope of the present invention. Any equivalent changes or modifications made based on the spirit and substance of the present invention shall be included in the protection scope of the present invention.

Claims

1. 1. An siRNA comprising a sense strand and an antisense strand, wherein each nucleotide in the siRNA is independently modified or unmodified, and the sense strand is siRNA comprising any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 12, or a nucleotide sequence having 3 or less base mutations in the above sequence, and the antisense strand comprising any one of the nucleotide sequences shown in SEQ ID NOs: 13 to 24, or a nucleotide sequence having 5 or less base mutations in the above sequence.

2. 2. The siRNA of claim 1, wherein, in the 5' to 3' direction, the base mutations in the sense strand are at the 3' end of the nucleotide sequence, and the base mutations in the antisense strand are at any one or more of the 5' end, positions 2 to 8, and the last two positions of the 3' end of the nucleotide sequence.

3. 2. The siRNA of claim 1, wherein the modified nucleotide is a 2'-methoxy modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-O-CH 2 -CH 2 -O-CH 3 Modified nucleotides, 2'-O-CH 2 -CH=CH 2 Modified nucleotides, 2'-CH 2 -CH 2 -CH=CH 2 Modified nucleotides, 2'-deoxynucleotides, 2'-methoxyethyl modified nucleotides, phosphorothioate bond modified nucleotides, VP modified nucleotides, LNA, ENA, cET BNA, UNA, GNA, and 【Chemistry 1】 wherein R1 is H, OH, or CH 3 wherein Base is a natural nucleobase, a modified nucleobase, a universal base, or an H atom.

4. 4. The siRNA according to claim 1, wherein one or more nucleotides in the sense strand or the antisense strand are modified nucleotides.

5. 4. The siRNA of any one of claims 1 to 3, wherein, in the 5' to 3' direction, the nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro modified nucleotides and the nucleotides at other positions of the sense strand are 2'-methoxy modified nucleotides; in the 5' to 3' direction, the nucleotides at positions 2, 14, and 16 of the antisense strand are 2'-fluoro modified nucleotides and the nucleotides at positions other than positions 2, 6, 7, 14, and 16 of the antisense strand are 2'-methoxy modified nucleotides; and at least one of the following internucleotide linkages in the siRNA is a phosphorothioate linkage: a linkage between a first nucleotide and a second nucleotide at the 5' end of the sense strand; a linkage between the second and third nucleotides at the 5' end of the sense strand; a bond between a first nucleotide and a second nucleotide at the 3' end of the sense strand; a linkage between the second and third nucleotides at the 3' end of the sense strand; a bond between a first nucleotide and a second nucleotide at the 5′ end of the antisense strand; a linkage between the second and third nucleotides at the 5' end of the antisense strand; a bond between a first nucleotide and a second nucleotide at the 3' end of the antisense strand; a linkage between the second and third nucleotides at the 3' end of the antisense strand; 1. An siRNA, wherein the 3'-end of the sense strand is a phosphorothioate group, and the 5'-end of the antisense strand is a VP-modified nucleotide.

6. 4. The siRNA according to claim 1, wherein, in the 5' to 3' direction, position 6 of the antisense strand is a 2'-fluoro modified nucleotide or 【Chemistry 2】 and position 7 of the antisense strand is a 2'-methoxy modified nucleotide or 【Transformation 3】 , where R1 is H, OH or CH 3 wherein Base is a natural nucleobase, a modified nucleobase, a universal base, or an H atom.

7. 7. The siRNA of claim 6, wherein the nucleotide at position 6 or 7 of the antisense strand is 【Chemistry 4】 1. An siRNA characterized by:

8. 2. The siRNA of claim 1, wherein the siRNA has one of the sequences shown in the table below: Table 1

9. 2. The siRNA of claim 1, wherein the siRNA has one of the sequences shown in the table below: Table 2

10. 2. The siRNA of claim 1, wherein the siRNA has one of the sequences shown in the table below: Table 3-1 Table 3-2

11. 11. An siRNA conjugate, characterized in that it comprises one or more siRNAs according to any one of claims 1 to 10 and a conjugate group conjugated to said siRNA.

12. 12. The siRNA conjugate according to claim 11, wherein the conjugate group is derived from compound SA51, the number of compounds SA51 in the conjugate group is 2 to 4, and the 2 to 4 compounds SA51 are sequentially linked via chemical bonds; the structural formula of the compound SA51 is: 【Transformation 5】 1. An siRNA conjugate, characterized in that:

13. 13. The siRNA conjugate of claim 11 or 12, wherein the conjugate group is linked to the 3'-end and / or the 5'-end of the sense strand.

14. 12. The siRNA conjugate of claim 11, wherein the structural formula of the siRNA conjugate is as follows: 【Transformation 6】

15. A pharmaceutical composition comprising the siRNA of any one of claims 1 to 10 or the siRNA conjugate of any one of claims 11 to 14, and a pharmaceutically acceptable carrier or excipient.

16. 16. The pharmaceutical composition according to claim 15, wherein said pharmaceutical composition is used to inhibit the expression of the programmed cell death ligand 1 gene.

17. Use of the siRNA according to any one of claims 1 to 10, or the siRNA conjugate according to any one of claims 11 to 14, or the pharmaceutical composition according to claim 15 or 16, for producing a medicament for treating and / or preventing a disease associated with PD-L1 gene expression.

18. 18. The use according to claim 17, wherein the disease is viral hepatitis or cancer.

19. 19. The use according to claim 18, wherein the viral hepatitis is caused by infection with hepatitis B virus, hepatitis C virus, or hepatitis D virus.

Citation Information

Patent Citations

  • Methods and compositions for targeting PD-l1

    WO2021173811A1